


## WHAT IS CLAIMED:

1. A compound represented by the structure of formula (I):



5 wherein

**A** and **B** rings are each independently a single or fused aromatic or heteroaromatic ring system, or a single or fused C<sub>3</sub>-C<sub>10</sub> cycloalkyl or a single or fused C<sub>3</sub>-C<sub>10</sub> heterocyclic ring;

- R<sub>1</sub>** and **R<sub>2</sub>** are each independently H, F, Cl, Br, I, OH, SH, R<sub>8</sub>-OH, R<sub>8</sub>-SH, -R<sub>8</sub>-O-R<sub>10</sub>, R<sub>8</sub>-(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), R<sub>8</sub>-(C<sub>3</sub>-C<sub>8</sub> heterocyclic ring), CF<sub>3</sub>, CD<sub>3</sub>, OCD<sub>3</sub>, CN, NO<sub>2</sub>, -CH<sub>2</sub>CN, -R<sub>8</sub>CN, NH<sub>2</sub>, NHR, N(R)<sub>2</sub>, R<sub>8</sub>-N(R<sub>10</sub>)(R<sub>11</sub>), R<sub>9</sub>-R<sub>8</sub>-N(R<sub>10</sub>)(R<sub>11</sub>), B(OH)<sub>2</sub>, -OC(O)CF<sub>3</sub>, -OCH<sub>2</sub>Ph, NHC(O)-R<sub>10</sub>, NHCO-N(R<sub>10</sub>)(R<sub>11</sub>), COOH, -C(O)Ph, C(O)O-R<sub>10</sub>, R<sub>8</sub>-C(O)-R<sub>10</sub>, C(O)H, C(O)-R<sub>10</sub>, C<sub>1</sub>-C<sub>5</sub> linear or branched C(O)-haloalkyl, -C(O)NH<sub>2</sub>, C(O)NHR, C(O)N(R<sub>10</sub>)(R<sub>11</sub>), SO<sub>2</sub>R, SO<sub>2</sub>N(R<sub>10</sub>)(R<sub>11</sub>), CH(CF<sub>3</sub>)(NH-R<sub>10</sub>), C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkenyl, C<sub>1</sub>-C<sub>5</sub> linear or branched, or C<sub>3</sub>-C<sub>8</sub> cyclic haloalkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched, or C<sub>3</sub>-C<sub>8</sub> cyclic alkoxy, optionally wherein at least one methylene group (CH<sub>2</sub>) in the alkoxy is replaced with an oxygen atom, C<sub>1</sub>-C<sub>5</sub> linear or branched thioalkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched haloalkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched alkoxyalkyl, substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub> heterocyclic ring, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, (wherein substitutions include: F, Cl, Br, I, C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, OH, alkoxy, N(R)<sub>2</sub>, CF<sub>3</sub>, aryl, phenyl, heteroaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, halophenyl, (benzyloxy)phenyl, CN, NO<sub>2</sub> or any combination thereof);

or **R<sub>2</sub>** and **R<sub>1</sub>** are joint together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring;

- R<sub>3</sub>** and **R<sub>4</sub>** are each independently H, F, Cl, Br, I, OH, SH, R<sub>8</sub>-OH, R<sub>8</sub>-SH, -R<sub>8</sub>-O-R<sub>10</sub>, -O-R<sub>8</sub>-R<sub>10</sub>, R<sub>8</sub>-(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), R<sub>8</sub>-(C<sub>3</sub>-C<sub>8</sub> heterocyclic ring), CF<sub>3</sub>, CD<sub>3</sub>, OCD<sub>3</sub>, CN, NO<sub>2</sub>, -CH<sub>2</sub>CN, -R<sub>8</sub>CN, NH<sub>2</sub>, NHR, N(R)<sub>2</sub>, R<sub>8</sub>-N(R<sub>10</sub>)(R<sub>11</sub>), R<sub>9</sub>-R<sub>8</sub>-N(R<sub>10</sub>)(R<sub>11</sub>), B(OH)<sub>2</sub>, -OC(O)CF<sub>3</sub>, -OCH<sub>2</sub>Ph, NHC(O)-R<sub>10</sub>, NHCO-N(R<sub>10</sub>)(R<sub>11</sub>), COOH, -C(O)Ph, C(O)O-R<sub>10</sub>, R<sub>8</sub>-C(O)-R<sub>10</sub>, C(O)H, C(O)-R<sub>10</sub>, C<sub>1</sub>-C<sub>5</sub> linear or branched C(O)-haloalkyl, -C(O)NH<sub>2</sub>, C(O)NHR, C(O)N(R<sub>10</sub>)(R<sub>11</sub>), SO<sub>2</sub>R, SO<sub>2</sub>N(R<sub>10</sub>)(R<sub>11</sub>), CH(CF<sub>3</sub>)(NH-R<sub>10</sub>), C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkenyl, C<sub>1</sub>-C<sub>5</sub> linear or branched, or C<sub>3</sub>-C<sub>8</sub> cyclic haloalkyl, substituted or unsubstituted C<sub>1</sub>-C<sub>5</sub> linear or branched, or C<sub>3</sub>-C<sub>8</sub> cyclic alkoxy, optionally wherein at least one methylene group (CH<sub>2</sub>) in the alkoxy is replaced with an oxygen atom, C<sub>1</sub>-C<sub>5</sub> linear or branched thioalkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched haloalkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched alkoxyalkyl, substituted or

unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub> heterocyclic ring, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, (wherein substitutions include: F, Cl, Br, I, C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, OH, alkoxy, N(R)<sub>2</sub>, CF<sub>3</sub>, aryl, phenyl, heteroaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, halophenyl, (benzyloxy)phenyl, CN, NO<sub>2</sub> or any combination thereof);

- 5 or **R<sub>3</sub>** and **R<sub>4</sub>** are joint together to form a 5 or 6 membered substituted or unsubstituted, aliphatic or aromatic, carbocyclic or heterocyclic ring;

**R<sub>5</sub>** is absent or is H, F, Cl, Br, I, OH, SH, R<sub>8</sub>-OH, R<sub>8</sub>-SH, -R<sub>8</sub>-O-R<sub>10</sub>, , R<sub>8</sub>-(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), R<sub>8</sub>-(C<sub>3</sub>-C<sub>8</sub> heterocyclic ring), CF<sub>3</sub>, CD<sub>3</sub>, OCD<sub>3</sub>, CN, NO<sub>2</sub>, -CH<sub>2</sub>CN, -R<sub>8</sub>CN, NH<sub>2</sub>, NHR, N(R)<sub>2</sub>, R<sub>8</sub>-N(R<sub>10</sub>)(R<sub>11</sub>), R<sub>9</sub>-R<sub>8</sub>-N(R<sub>10</sub>)(R<sub>11</sub>), B(OH)<sub>2</sub>, -OC(O)CF<sub>3</sub>, -OCH<sub>2</sub>Ph, NHC(O)-R<sub>10</sub>, NHCO-N(R<sub>10</sub>)(R<sub>11</sub>),  
 10 COOH, -C(O)Ph, C(O)O-R<sub>10</sub>, R<sub>8</sub>-C(O)-R<sub>10</sub>, C(O)H, C(O)-R<sub>10</sub>, C<sub>1</sub>-C<sub>5</sub> linear or branched C(O)-haloalkyl, -C(O)NH<sub>2</sub>, C(O)NHR, C(O)N(R<sub>10</sub>)(R<sub>11</sub>), SO<sub>2</sub>R, SO<sub>2</sub>N(R<sub>10</sub>)(R<sub>11</sub>), CH(CF<sub>3</sub>)(NH-R<sub>10</sub>), C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkenyl, C<sub>1</sub>-C<sub>5</sub> linear or branched, or C<sub>3</sub>-C<sub>8</sub> cyclic haloalkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched, or C<sub>3</sub>-C<sub>8</sub> cyclic alkoxy, optionally wherein at least one methylene group (CH<sub>2</sub>) in the alkoxy is replaced with an oxygen  
 15 atom, C<sub>1</sub>-C<sub>5</sub> linear or branched thioalkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched haloalkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched alkoxyalkyl, substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub> heterocyclic ring, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, (wherein substitutions include: F, Cl, Br, I, C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, OH, alkoxy, N(R)<sub>2</sub>, CF<sub>3</sub>, aryl, phenyl, heteroaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, halophenyl, (benzyloxy)phenyl, CN, NO<sub>2</sub> or any combination thereof);

20 **R<sub>6</sub>** and **R<sub>7</sub>** are each independently H, F, Cl, Br, I, OH, SH, R<sub>8</sub>-OH, R<sub>8</sub>-SH, -R<sub>8</sub>-O-R<sub>10</sub>, , R<sub>8</sub>-(C<sub>3</sub>-C<sub>8</sub> cycloalkyl), R<sub>8</sub>-(C<sub>3</sub>-C<sub>8</sub> heterocyclic ring), CF<sub>3</sub>, CD<sub>3</sub>, OCD<sub>3</sub>, CN, NO<sub>2</sub>, -CH<sub>2</sub>CN, -R<sub>8</sub>CN, NH<sub>2</sub>, NHR, N(R)<sub>2</sub>, R<sub>8</sub>-N(R<sub>10</sub>)(R<sub>11</sub>), R<sub>9</sub>-R<sub>8</sub>-N(R<sub>10</sub>)(R<sub>11</sub>), B(OH)<sub>2</sub>, -OC(O)CF<sub>3</sub>, -OCH<sub>2</sub>Ph, NHC(O)-R<sub>10</sub>, NHCO-N(R<sub>10</sub>)(R<sub>11</sub>), COOH, -C(O)Ph, C(O)O-R<sub>10</sub>, R<sub>8</sub>-C(O)-R<sub>10</sub>, C(O)H, C(O)-R<sub>10</sub>, C<sub>1</sub>-C<sub>5</sub> linear or branched C(O)-haloalkyl, -C(O)NH<sub>2</sub>, C(O)NHR, C(O)N(R<sub>10</sub>)(R<sub>11</sub>), SO<sub>2</sub>R, SO<sub>2</sub>N(R<sub>10</sub>)(R<sub>11</sub>), CH(CF<sub>3</sub>)(NH-R<sub>10</sub>),  
 25 C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkenyl, C<sub>1</sub>-C<sub>5</sub> linear or branched, or C<sub>3</sub>-C<sub>8</sub> cyclic haloalkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched, or C<sub>3</sub>-C<sub>8</sub> cyclic alkoxy, optionally wherein at least one methylene group (CH<sub>2</sub>) in the alkoxy is replaced with an oxygen atom, C<sub>1</sub>-C<sub>5</sub> linear or branched thioalkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched haloalkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched alkoxyalkyl, substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted or  
 30 unsubstituted C<sub>3</sub>-C<sub>8</sub> heterocyclic ring, substituted or unsubstituted aryl, substituted or unsubstituted benzyl, (wherein substitutions include: F, Cl, Br, I, C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, OH, alkoxy, N(R)<sub>2</sub>, CF<sub>3</sub>, aryl, phenyl, heteroaryl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, halophenyl, (benzyloxy)phenyl, CN, NO<sub>2</sub> or any combination thereof);

- or **R<sub>6</sub>** and **R<sub>7</sub>** are joint together to form a 3 to 6 membered substituted or unsubstituted, aliphatic  
 35 or aromatic, carbocyclic or heterocyclic ring;

**Q<sub>1</sub>** is NH, N(R), S, O, N-OH or N-OMe;

**Q<sub>2</sub>** is N, or C(R);

**R** is H, F, Cl, Br, I, OH, SH, OH, alkoxy, N(R)<sub>2</sub>, CF<sub>3</sub>, CN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched alkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched haloalkyl, R<sub>8</sub>-aryl, -R<sub>8</sub>-O-R<sub>8</sub>-O-R<sub>10</sub>, -R<sub>8</sub>-O-R<sub>10</sub>, -R<sub>8</sub>-R<sub>10</sub>, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, (wherein substitutions include: F, Cl, Br, I, OH, SH, C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, OH, alkoxy, N(R)<sub>2</sub>, CF<sub>3</sub>, phenyl, halophenyl, (benzyloxy)phenyl, CN, NO<sub>2</sub> or any combination thereof);

**G=X** is C=O, C=S, S=O, SO<sub>2</sub>, CH<sub>2</sub>, CHR, or C(R)<sub>2</sub>;

each **R<sub>8</sub>** is independently [CH<sub>2</sub>]<sub>p</sub>

wherein **p** is between 1 and 10;

**R<sub>9</sub>** is [CH]<sub>q</sub>, [C]<sub>q</sub>

wherein **q** is between 2 and 10;

**R<sub>10</sub>** and **R<sub>11</sub>** are each independently H, C<sub>1</sub>-C<sub>5</sub> substituted or unsubstituted linear or branched alkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched alkoxy, C(O)R, or S(O)<sub>2</sub>R; or **R<sub>10</sub>** and **R<sub>11</sub>** are joint to form a substituted or unsubstituted C<sub>3</sub>-C<sub>8</sub> heterocyclic ring,

wherein substitutions include: F, Cl, Br, I, OH, C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl, C<sub>1</sub>-C<sub>5</sub> linear or branched alkyl-OH, C<sub>3</sub>-C<sub>8</sub> heterocyclic ring, alkoxy, N(R)<sub>2</sub>, CF<sub>3</sub>, aryl, phenyl, halophenyl, (benzyloxy)phenyl, CN, NO<sub>2</sub> or any combination thereof

**m**, **n**, **l** and **k** are each independently an integer between 0 and 4 ;


**X<sub>6</sub>**, **X<sub>7</sub>** and **X<sub>8</sub>** are each independently C or N;

**X<sub>14</sub>** and **X<sub>15</sub>** are each independently C or N;

or its pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, *N*-oxide, reverse amide analog, prodrug, isotopic variant, PROTAC, pharmaceutical product or any combination thereof;

wherein **R<sub>5</sub>** can only be attached to **X<sub>6</sub>**, **X<sub>7</sub>** and/or **X<sub>8</sub>** that are C.

2. The compound of claim 1, represented by the structure of formula **I(a)**:




wherein

$X_1$ ,  $X_2$ ,  $X_3$ ,  $X_4$ , and  $X_5$ , are each independently C or N


or its pharmaceutically acceptable salt, optical isomer, tautomer, hydrate, *N*-oxide, reverse amide analog, prodrug, isotopic variant, PROTAC, pharmaceutical product or any combination thereof.

3. The compound of claim 1 or 2, represented by the structure of formula **I(b)**:



**I(b).**

4. The compound of any one of claims 1 to 3, represented by the structure of formula **I(c)**:




**I(c)**

wherein

$X_9$ ,  $X_{10}$ ,  $X_{11}$ ,  $X_{12}$ , and  $X_{13}$  are each independently C or N.

5. The compound of claim 1, represented by the structure of formula **I(d)**:




**I(d)**

wherein

$R_{12}$  is H, a  $C_1$ - $C_5$  linear or branched, substituted or unsubstituted alkyl, F, Cl, Br, I, OH, SH, OH,  $N(R)_2$ ,  $CF_3$ , CN,  $NO_2$ ,  $C_1$ - $C_5$  linear or branched alkoxy,  $C_1$ - $C_5$  linear or branched haloalkyl or  $C_3$ - $C_8$  cycloalkyl.

6. The compound of claim 1, represented by the structure of formula **I(e)**:




**I(e)**

wherein

**R<sub>12</sub>** is H, a C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkyl, F, Cl, Br, I, OH, SH, OH, N(R)<sub>2</sub>, CF<sub>3</sub>, CN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>5</sub> linear or branched alkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched haloalkyl or C<sub>3</sub>-C<sub>8</sub> cycloalkyl.

7. The compound of claim 1, represented by the structure of formula **I(f)**:

5




**I(f).**

wherein

**A'** ring is a 5 (five) membered heteroaromatic, or a heterocyclic ring.

8. The compound according to any one of claims 1, 5 and 7, represented by the structure of formula **I(d(i))**:

10




**I(d(i))**

wherein

**R<sub>12</sub>** is H, a C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkyl, F, Cl, Br, I, OH, SH, OH, N(R)<sub>2</sub>, CF<sub>3</sub>, CN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>5</sub> linear or branched alkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched haloalkyl or C<sub>3</sub>-C<sub>8</sub> cycloalkyl.

15

9. The compound according to any one of claims 1, 6 and 7, represented by the structure of formula **I(e(i))**:



**I(e(i))**









20









wherein









**R<sub>12</sub>** is H, a C<sub>1</sub>-C<sub>5</sub> linear or branched, substituted or unsubstituted alkyl, F, Cl, Br, I, OH, SH, OH, N(R)<sub>2</sub>, CF<sub>3</sub>, CN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>5</sub> linear or branched alkoxy, C<sub>1</sub>-C<sub>5</sub> linear or branched haloalkyl or C<sub>3</sub>-C<sub>8</sub> cycloalkyl.









10. The compound of claim 1, selected from the following:









| Compound Number | Compound Structure |
|-----------------|--------------------|
|-----------------|--------------------|









|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 100 |    |
| 101 |    |
| 102 |    |
| 103 |    |
| 104 |  |
| 105 |  |
| 106 |  |
| 109 |  |








|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 110 |    |
| 111 |    |
| 112 |    |
| 113 |   |
| 114 |  |
| 115 |  |
| 116 |  |
| 117 |  |







|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 118 |    |
| 119 |    |
| 120 |    |
| 121 |   |
| 122 |  |
| 123 |  |
| 124 |  |
| 125 |  |










|                |                                                                                      |
|----------------|--------------------------------------------------------------------------------------|
| 126            |    |
| 127            |    |
| 128            |    |
| 129            |   |
| 130            |  |
| 131            |  |
| 132 (Isomer 2) |  |
| 133            |  |











|                |                                                                                      |
|----------------|--------------------------------------------------------------------------------------|
| 134 (Isomer 1) |    |
| 135            |    |
| 136            |    |
| 137            |    |
| 139            |   |
| 140            |  |
| 141            |  |
| 142            |  |











|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 143 |    |
| 144 |    |
| 145 |    |
| 146 |   |
| 147 |  |
| 148 |  |
| 149 |  |
| 150 |  |

|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 151 |    |
| 152 |    |
| 154 |    |
| 155 |   |
| 156 |  |
| 157 |  |
| 158 |  |











|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 159 |    |
| 160 |    |
| 161 |   |
| 162 |  |
| 163 |  |
| 164 |  |










|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 165 |    |
| 166 |    |
| 167 |    |
| 168 |    |
| 169 |   |
| 170 |  |
| 171 |  |
| 173 |  |
| 174 |  |









|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 175 |    |
| 176 |    |
| 177 |    |
| 178 |    |
| 179 |   |
| 180 |  |
| 181 |  |
| 182 |  |
| 183 |  |
| 184 |  |









|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 185 |    |
| 186 |    |
| 187 |    |
| 188 |    |
| 189 |   |
| 190 |  |
| 191 |  |
| 192 |  |
| 193 |  |
| 194 |  |








|     |  |
|-----|--|
| 195 |  |
| 196 |  |
| 197 |  |
| 198 |  |
| 199 |  |
| 200 |  |
| 201 |  |
| 202 |  |
| 203 |  |
| 204 |  |
| 205 |  |

|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 206 |    |
| 207 |    |
| 208 |    |
| 209 |    |
| 210 |    |
| 211 |   |
| 212 |  |
| 213 |  |
| 214 |  |
| 215 |  |



|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 216 |    |
| 217 |    |
| 218 |    |
| 219 |    |
| 220 |   |
| 221 |  |
| 222 |  |
| 223 |  |
| 224 |  |

|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 225 |    |
| 227 |    |
| 229 |    |
| 230 |   |
| 231 |  |
| 232 |  |
| 233 |  |
| 234 |  |

|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 235 |    |
| 236 |    |
| 237 |    |
| 238 |    |
| 239 |   |
| 240 |  |
| 241 |  |
| 242 |  |

|     |                                                                                      |
|-----|--------------------------------------------------------------------------------------|
| 243 |    |
| 244 |    |
| 245 |    |
| 246 |   |
| 247 |  |
| 248 |  |
| 249 |  |

11. A compound represented by the structure of the following compounds:

| Compound Number | Compound Structure                                                                 |
|-----------------|------------------------------------------------------------------------------------|
| 138             |  |
| 153             |  |

12. The compound according to any one of claims 1-3, 5 and 6, wherein **B** is tetrahydropyrane, pyridinyl or phenyl.
13. The compound according to any one of claims 1-9, wherein **l** is 1 and **k** is 0.
14. The compound according to any one of claims 1-9, wherein **R<sub>3</sub>** is H, CH<sub>3</sub> or CF<sub>3</sub>.
15. The compound according to claim 1, wherein **A** is pyrimidine or pyrazolyl.
16. The compound according to any one of claims 1-2 and 7, wherein **n** is 1 and **m** is 0.
17. The compound according to any one of claims 1-9, wherein **R<sub>1</sub>** is CH<sub>3</sub>.
18. The compound according to any one of claims 1-3, wherein **Q<sub>1</sub>** is NH or N(R), and **R** is CH<sub>3</sub>.
19. The compound according to claims 2 or 3, wherein **X<sub>2</sub>** and **X<sub>4</sub>** are N and **X<sub>1</sub>**, **X<sub>3</sub>** and **X<sub>5</sub>** are C.
20. The compound according to any one of claims 1-3, wherein **G=X** is C=O.
21. The compound according to any one of claims 1-20, wherein the compound is a collagen translation inhibitor.
22. A pharmaceutical composition comprising a compound according to any one of claims 1 to 21 and a pharmaceutically acceptable carrier.
23. A compound according to any one of claims 1 to 21, for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting fibrosis in a subject.
24. The compound of claim 23, wherein said fibrosis is a systemic fibrotic disease.
25. The compound of claim 24, wherein said systemic fibrotic disease is systemic sclerosis, multifocal fibrosclerosis (IgG4-associated fibrosis), nephrogenic systemic fibrosis, sclerodermatous graft vs. host disease, or any combination thereof.
26. The compound of claim 23, wherein said fibrosis is an organ-specific fibrotic disease.

27. The compound of claim 26, wherein said organ-specific fibrotic disease is lung fibrosis, cardiac fibrosis, kidney fibrosis, pulmonary fibrosis, liver and portal vein fibrosis, radiation-induced fibrosis, bladder fibrosis, intestinal fibrosis, peritoneal sclerosis, diffuse fasciitis, wound healing, scarring, or any combination thereof.
- 5 28. The compound of claim 27, wherein said lung fibrosis is Idiopathic pulmonary fibrosis (IPF).
29. The compound of claim 27, wherein said cardiac fibrosis is hypertension-associated cardiac fibrosis, Post-myocardial infarction, Chagas disease-induced myocardial fibrosis or any combination thereof.
30. The compound of claim 27, wherein said kidney fibrosis is diabetic and hypertensive nephropathy, urinary tract obstruction-induced kidney fibrosis, inflammatory/autoimmune-induced kidney fibrosis, 10 aristolochic acid nephropathy, polycystic kidney disease, or any combination thereof.
31. The compound of claim 27, wherein said pulmonary fibrosis is idiopathic pulmonary fibrosis, silica-induced pneumoconiosis (silicosis), asbestos-induced pulmonary fibrosis (asbestosis), chemotherapeutic agent-induced pulmonary fibrosis, or any combination thereof.
32. The compound of claim 27, wherein said liver and portal vein fibrosis is alcoholic and nonalcoholic 15 liver fibrosis, hepatitis C-induced liver fibrosis, primary biliary cirrhosis, parasite-induced liver fibrosis (schistosomiasis), or any combination thereof.
33. The compound of claim 27, wherein said diffuse fasciitis is localized scleroderma, keloids, dupuytren's disease, peyronie's disease, myelofibrosis, oral submucous fibrosis, or any combination thereof.
34. The compound of claim 23, wherein said fibrosis is primary or secondary fibrosis.
- 20 35. The compound of claim 23 wherein said fibrosis is a result of systemic sclerosis, graft-versus host disease (GVHD), pulmonary fibrosis, autoimmune disorder, tissue injury, inflammation, oxidative stress or any combination thereof.
36. The compound of claim 23, wherein the fibrosis is hepatic fibrosis, lung fibrosis or dermal fibrosis.
37. The compound of any one of claims 23 or 32, wherein said subject has a liver cirrhosis.
- 25 38. The compound of claim 36, wherein the dermal fibrosis is scleroderma.
39. The compound of claim 36, wherein the dermal fibrosis is a result of a localized or generalized morphea, keloids, hypertrophic scars, familial cutaneous collagenoma, connective tissue nevi of the collagen type, or any combination thereof.
40. The compound of claim 36, wherein the hepatic fibrosis is a result of hepatic scarring or chronic liver 30 injury.
41. The compound of claim 40, wherein the chronic liver injury results from alcoholism, malnutrition, hemochromatosis, exposure to poisons, toxins or drugs.
42. The compound according to any one of claims 1 to 21, for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting lung fibrosis in a subject.
- 35 43. The compound of claim 42, wherein the lung fibrosis is Idiopathic pulmonary fibrosis (IPF).
44. The compound according to any one of claims 1 to 21, for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting Idiopathic pulmonary fibrosis (IPF) in a subject.

45. The compound according to any one of claims 1 to 21, for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting hepato-fibrotic disorder in a subject.
46. The compound of claim 45, wherein the hepato-fibrotic disorder is a portal hypertension, cirrhosis, congenital hepatic fibrosis or any combination thereof.
- 5 47. The compound according to any one of claims 1 to 21, for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting cirrhosis in a subject.
48. The compound of claim 47, wherein the cirrhosis is a result of hepatitis or alcoholism.
49. The compound according to any one of claims 1 to 21, for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting alcoholic steatohepatitis (ASH) in a subject.
- 10 50. The compound according to any one of claims 1 to 21, for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting non-alcoholic steatohepatitis (NASH) in a subject.
51. The compound according to any one of claims 1 to 21, for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting alcoholic fatty liver disease (AFLD) in a subject.
- 15 52. The compound according to any one of claims 1 to 21, for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting non alcoholic fatty liver disease (NAFLD) in a subject.
53. The compound according to any one of claims 1 to 21, for use in treating, suppressing, reducing the severity, reducing the risk of developing or inhibiting an autoimmune disease or disorder in a subject.

20